Short communication: Evaluating roles of plasma glial fibrillary acidic protein as Alzheimer's disease biomarker in real-world multi-center memory clinics in Thailand.

The roles of reactive astrocytes in Alzheimer's disease (AD) and the correlation between plasma glial fibrillary acidic protein (GFAP) and amyloid-β are emerging. Among 133 patients with cognitive complaints from multi-center memory clinics in Thailand, 73 had AD as defined either by cerebrospinal fluid core biomarkers or amyloid PET. Plasma GFAP demonstrated an AUC of 0.74 (95%CI: 0.65-0.83) for detecting AD and showed large effects on identifying AD status with Cohen's d = 0.81 (95%CI 0.44-1.18). LOESS regression illustrated that plasma GFAP increased from the early stages of AD. Plasma GFAP has potential applications across diverse populations.